trending Market Intelligence /marketintelligence/en/news-insights/trending/L27VvcCmS2Wc3EKRM94YNg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

ImmunoPrecise to buy privately held contract research company for €2.3M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


ImmunoPrecise to buy privately held contract research company for €2.3M

ImmunoPrecise Antibodies Ltd. signed a binding letter of intent to buy all the issued and outstanding shares of German contract research company Preclinics GmbH for €2.3 million.

Under the proposed deal, ImmunoPrecise would pay 35% of the deal value for the privately held company in cash and the remaining in form of ImmunoPrecise company shares on closing of the transaction.

The company will pay an additional €750,000 in succession payments over three years based on continued profitability, with an option for Preclinics' shareholders to take the payments in cash or equity.

In addition, the deal requires ImmunoPrecise to fund Preclinics after the completion of the transaction and to enter into a separate agreement with Preclinics shareholders on the development and commercialization of Immunojunction.

The CEO and CFO of Preclinics will also enter into a three-year management contract, which will include nonsolicitation and noncompetition clauses.

The parties will carry out due diligence until Feb. 28, 2018, after which they may enter into a definitive agreement regarding the transaction.